AC
Accustem Sciences Inc.
ACUT · OTC
$0.12 +0.00% (+$0.00)
1M -13.56%
Market Cap $1.93M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.15
25.0% upside
Current Price
$0.12
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ACUT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 19.60x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
Net margin 1,680.03%
Op. margin 1,780.03%
Quality
58 /100
Average ROIC 43.20%
ROA 102.92%
Asset turnover 0.06x
Debt
0 /100
High Current ratio 0.02x
Debt/Equity N/A
Int. coverage N/A
Stability
39 /100
Moderate Beta 1.87x
EPS volatility 19.68%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ACUT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Wendy E. Blosser
Employees
4
Headquarters
New York City